Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2010
03/10/2010EP0932678B2 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
03/10/2010CN101668561A Formulations for cancer treatment
03/10/2010CN101665536A Anti-vegf antibodies
03/10/2010CN101664388A transnasal transport/immunisation with highly adaptable carriers
03/10/2010CN100593401C Combination of an aromatase inhibitor with a bisphosphonate
03/09/2010US7674903 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
03/09/2010US7674886 Chelation compounds, radionuclides
03/09/2010US7674830 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
03/09/2010US7674823 DNA-PK inhibitors
03/09/2010US7674796 Inhibitors of the FAK (focal adhesion kinase) protein tyrosine kinases, antiproliferative, antitumor; for example 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one
03/09/2010US7674795 Fluorene derivatives, composition containing said derivatives and the use thereof
03/09/2010US7674790 Processes of making and using pharmaceutical formulations of antineoplastic agents
03/09/2010US7674788 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors
03/09/2010US7674777 Immunostimulatory nucleic acid molecules
03/09/2010US7674775 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants
03/09/2010US7674487 Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof
03/09/2010US7674468 Herpes simplex virus (HSV) comprising deletion, insertion, or substitution in each gamma 34.5 gene; lysis
03/09/2010US7674463 Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist
03/09/2010US7674462 Transforming growth factor receptor specific immunoglobulin for use in diagnosis prvention and treatment of tumor disorders; immunotherapy
03/09/2010US7674456 Breast cancer cell lines and uses thereof
03/09/2010CA2425572C Process and intermediates for the production of 7-substituted antiestrogens
03/09/2010CA2399813C Indol-3-yl derivatives
03/09/2010CA2306313C Dipeptide nitriles
03/09/2010CA2172153C Regulation of bcl-2 gene expression
03/04/2010WO2010025436A2 Nitrogen and sulfur-containing heterocycle derivatives
03/04/2010WO2010025324A2 Nanoparticles for immunotherapy
03/04/2010WO2010025138A2 Pyrimidine compounds
03/04/2010WO2010025135A2 Trimeprazine and ethopropazine derivatives for promoting bone growth
03/04/2010WO2010025073A1 Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
03/04/2010WO2010025050A2 Affecting bone related conditions using cd68 blocking agents
03/04/2010WO2010024930A2 Cortistatin analogues and syntheses therof
03/04/2010WO2010024783A1 Biarylrhodanine and pyridylrhodanine compounds and their use
03/04/2010WO2010024775A1 New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis
03/04/2010WO2010024719A1 Process for preparing an anti-tumour vaccine
03/04/2010WO2010024711A1 Method for treating oncological diseases
03/04/2010WO2010024676A1 Delivery of a cd40 agonist to a tumor draining lymph node of a subject
03/04/2010WO2010024262A1 Transfection agent
03/04/2010WO2010024258A1 Ring-fused azole derivative having pi3k-inhibiting activity
03/04/2010WO2010024118A1 Novel recombinant protein having caspase recruitment domain applied thereto, and use thereof
03/04/2010WO2010023946A1 Novel uracil compound having nitrogenated heterocyclic ring or salt thereof
03/04/2010WO2010023917A1 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof
03/04/2010WO2010023866A1 Syngr4 for target genes of cancer therapy and diagnosis
03/04/2010WO2010023854A1 Cancer related gene, lgn/gpsm2
03/04/2010WO2010023850A1 Method for treating or preventing bladder cancer using the depdc1 polypeptide
03/04/2010WO2010023838A1 Tbc1d7 as tumor marker and therapeutic target for cancer
03/04/2010WO2010023837A1 Breast cancer related gene rqcd1
03/04/2010WO2010023716A1 Microbial culture having anticancer effect and product using the microbial culture
03/04/2010WO2010023480A1 Saturated bicyclic heterocyclic derivatives as smo antagonists
03/04/2010WO2010023474A1 Novel polymorphs of sunitinib and processes for their preparation
03/04/2010WO2010023473A2 Novel crystalline form and processes for its preparation
03/04/2010WO2010023347A1 Anti-tumour compounds
03/04/2010WO2010023346A1 Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses
03/04/2010WO2010023162A1 Process for extraction of glucosinolate s from broccoli seeds
03/04/2010WO2010022988A1 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b
03/04/2010WO2010022737A1 Anti-cd5 antibodies
03/04/2010WO2010022725A1 Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
03/04/2010WO2010022639A1 Target-specific double-mutant fusion protein
03/04/2010WO2010005585A3 4-aminoquinazoline prodrugs
03/04/2010WO2010004215A3 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof
03/04/2010WO2010004198A3 Antineoplastic derivatives of 4-oxo-l, 4-dihydro-quinolinξ, preparation thereof, and therapeutic use thereof
03/04/2010WO2009156860A3 4-(pyridin-4-yl)-1h-(1, 3, 5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
03/04/2010WO2009156179A8 Her3 as a determinant for the prognosis of melanoma
03/04/2010WO2009152210A3 Coumarin compounds and their use for treating cancer
03/04/2010WO2009149306A9 Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds
03/04/2010WO2009149094A3 Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
03/04/2010WO2009148620A3 Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
03/04/2010WO2009143454A3 Combination antitumor therapy
03/04/2010WO2009143211A3 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
03/04/2010WO2009143078A9 Methods of treating brain cancer using hexose compounds
03/04/2010WO2009140553A3 Hypoxia activated drugs of nitrogen mustard alkylators
03/04/2010WO2009140131A3 Compliant composites for application of drug-eluting coatings to tissue surfaces
03/04/2010WO2009139599A3 Cell-permeable p27 recombinant protein, a polynucleotide that codes the same and an anti-cancer composition containing the same as an active ingredient
03/04/2010WO2009138780A3 Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer
03/04/2010WO2009138601A3 Use of mannose-6-phosphate for controlling angiogenesis, ligament regeneration, and cartilage reconstruction
03/04/2010WO2009137471A3 Azo dye related small molecule modulators of protein-protein interactions
03/04/2010WO2009137378A3 Sequential administration of chemotherapeutic agents for treatment of cancer
03/04/2010WO2009135199A3 Vaccine compositions and methods
03/04/2010WO2009134428A3 Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
03/04/2010WO2009046294A3 Treatment of proliferative disorders using antibodies to psma
03/04/2010WO2009025876A8 Crystalline forms of erlotinib hcl and formulations thereof
03/04/2010WO2009023955A8 Cytotoxicity mediation of cells evidencing surface expression of cd9
03/04/2010US20100058488 Protein formulations comprising s1-5
03/04/2010US20100056635 Novel protein kinase modulators and therapeutic uses thereof
03/04/2010US20100056625 Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
03/04/2010US20100056623 Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
03/04/2010US20100056616 Iejimalid analoga and uses thereof
03/04/2010US20100056599 Substituted indeno[1,2-b]indole derivatives as novel inhibitors of protein kinase ck2 and their use as tumor therapeutic agents, cytostatics and diagnostic aids
03/04/2010US20100056592 Prodrugs of (3,5-bis(4-fluorophenyl)tetrahydro-1h-oxazolo[3,4-c]oxazol-7a-yl)methanol and derivatives thereof
03/04/2010US20100056585 N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzamide (MS-275) Polymorph B
03/04/2010US20100056571 Novel pyrazole compounds as transforming growth factor (tgf) inhibitors
03/04/2010US20100056558 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors
03/04/2010US20100056557 Treatment for cutaneous metastases
03/04/2010US20100056556 Isoquinolinopyrrolopyridinones active as kinase inhibitors
03/04/2010US20100056555 Method of treating ras associated cancer
03/04/2010US20100056553 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
03/04/2010US20100056551 Anti-cancer cyclopenta [G] quinazoline compounds
03/04/2010US20100056549 Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
03/04/2010US20100056548 Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
03/04/2010US20100056545 Novel phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of t-type calcium ion channel containing the same as an active ingredient
03/04/2010US20100056533 18f-labelled folates
1 ... 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 ... 2211